At Health Tech Enterprise we believe in improving healthcare through technology and innovation
Dignity Care Founded by Laura Corcoran, Dignity Care have developed the Miscarriage Collection Cradle; a patented, Class I Medical Device designed to restore dignity , privacy, and clinical safety to the miscarriage process. Enabled by the RTO grant from UK Edge Innovate UK Business Growth, Health Tech Enterprise has collaborated with Dignity Care to develop […]
Health Tech Enterprise provided Open Medical with a SIMUL8-based waiting list simulation, enabling them to assess the mean impact of their teledermoscopy tool on patient waiting times compared to the current standard of care. This innovation showed potential to significantly reduce waiting times for skin cancer diagnoses. The comprehensive report detailed the methodology, provided key insights from the simulation outcomes, and included actionable recommendations to strengthen the evidence base for their technology.
The client had a novel product for use in patients with irritable bowel syndrome (IBS) and wished to have its product listed on the NHS Drug Tariff. To support the application, a health economic evaluation was required to demonstrate the relative cost-effectiveness of the intervention.
The team at the Electrospinning Company have developed a novel synthetic material intended for use as a graft in ophthalmic surgery. The innovative material has the potential to improve surgical outcomes in addition to being more economical that the currently used graft options.
An innovator has developed a smart referral solution. The innovation is expected to enhance efficiencies in primary and secondary care by reducing inappropriate referrals, excessive secondary care appointments, repeat GP consultations, and the administrative burden associated with triaging and managing incorrect referrals.
The innovators had developed a digital dietary education program, targeting adults with a BMI greater than 25. The program is accessible through a website and also on a mobile app, it offers structured meal plans to the user.
The innovators at Aker Health Tech have developed an automated, self-propelled robotic colonoscopy device, capable of performing a complete colonoscopy for the lower gastrointestinal tract. This innovation is projected to significantly reduce the duration of the colonoscopy procedure and the required staffing resources.
Digistain have developed an innovative tumour-grading technology that has the potential to revolutionize breast cancer treatment. This technology enables the stratification of patients based on their risk of cancer recurrence, aiming to reduce the amount of unnecessary chemotherapy treatments that are delivered.
Neu Health developed a digital platform for people with Parkinson’s and dementia. The innovation facilitates patient empowerment and enables clinicians to close the care management and data gap between clinic visits, as well as reduce unnecessary journeys for both patients and healthcare professionals.
Our client developed an innovative tumour-grading technology that enables the stratification of patients based on their risk of cancer recurrence, guiding the use of chemotherapy. The client sought to understand the quantitative evidence on the reduction of carbon footprint resulting from decreased patient travel and improved logistics.
Lucida Medical develops software based on artificial intelligence methods (machine learning and image processing) to enable radiologists to find cancer accurately, consistently, and quickly using MRI. Innovators at Lucida Medical developed Prostate Intelligence (PI™) to support the diagnosis of prostate cancer in patients.
Innovators from the Department of Clinical Neurosciences at the University of Cambridge had developed a machine learning algorithm to predict the speed of progression of Alzheimer’s disease. This decision support tool would enable physicians to better manage their patients by assigning them to the most appropriate treatment pathway.
ONX is a non-invasive molecular test developed by UK based Cambridge Oncometrix. The test will enable risk-stratification and improve true positive rates within the diagnostic pathway for those with suspected prostate cancer. ONX will be conducted prior to multi-parametric magnetic resonance imaging scanning, a relatively new prostate cancer screening method. As a result, ONX will alleviate the burden placed on access to mpMRI scans.
Health Tech Enterprise is a trademark of Health Tech Enterprise Ltd.
© 2026 Health Tech Enterprise Ltd, St John's Innovation Centre, Cowley Road, Cambridge CB4 0WS
Email: enquiries@healthtechenterprise.co.uk Tel: +44 (0) 1223 420 252